KALA BIO, Inc. — Director's Dealing 2023

Jun 3, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2023-05-31

Reporting Person: Farid Marjan (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-31	Common Stock	A	1600	—	Acquired	1600	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-31	Stock Option (right to buy)	$6.35	D	1600	Disposed	2032-10-30	Common Stock (1600)	Direct

Footnotes

F1: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange for the unvested options, the reporting person received a grant of 1,600 RSUs that vest over three years, with 86% of such RSUs vesting on May 31, 2025 and 14% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F2: Includes 1,600 unvested RSUs.

F3: The cancelled option was granted on October 31, 2022 and provided for vesting with respect to 1/3rd of the shares underlying the option on October 31, 2023 and as to an additional 1/36th of the shares underlying the option at the end of each successive one-month period thereafter until October 31, 2025.